Indications for EPIVIR:
HIV infection.
Adults and Children's Dose:
≤3months: not recommended. 3months–16years: 4mg/kg (max 150mg) twice daily; renal impairment: reduce dose or prolong dosing interval. ≥16years, CrCl ≥50mL/min: 300mg once daily or 150mg twice daily; CrCl 30–49mL/min: 150mg once daily; CrCl 15–29mL/min: 150mg for 1st dose then 100mg once daily; CrCl 5–14mL/min: 150mg for 1st dose then 50mg once daily; CrCl <5mL/min: 50mg for 1st dose then 25mg once daily.
See Also:
EPIVIR ORAL SOLUTION
Pharmacological Class:
Nucleoside analogue (reverse transcriptase inhibitor).
Warnings/Precautions:
Discontinue if pancreatitis (increased risk in pediatric patients) or lactic acidosis occurs. Suspend therapy if hepatotoxicity (eg, hepatomegaly, steatosis) occurs. Women, obesity, or prolonged nucleoside exposure: increased risk of toxicity (ie, lactic acidosis, steatosis). Hepatitis B (monitor for post-treatment exacerbation). Other liver disease risk factors. Diabetes (oral soln). Children with prior antiretroviral nucleoside exposure, history of pancreatitis or risk factors for pancreatitis. Pregnancy (Cat.C). Nursing mothers: not recommended.
Interactions:
Concomitant zalcitabine: not recommended. Avoid concomitant drugs that contain lamivudine or emtricitabine. Caution with drugs eliminated by active organic cationic secretion (eg, trimethoprim). Increased lamivudine absorption with TMP/SMX (clinical significance unknown). Triple therapy (once daily regimen) with abacavir + tenofovir or with didanosine + tenofovir: high rate of early viral non-response (see literature). Monitor for treatment-associated toxicities with interferon-alpha with or without ribavirin.
Adverse Reactions:
Adults: headache, malaise, fever, GI upset, neuropathy, dizziness, sleep or depressive disorders, rash, respiratory effects, musculoskeletal pain, lactic acidosis, severe hepatomegaly with steatosis, fat redistribution, neutropenia, abnormal liver function tests. Children: pancreatitis, paresthesias, peripheral neuropathy, fever, rash, respiratory effects, neutropenia, anemia, abnormal liver function tests.
Note:
Register pregnant patients exposed to lamivudine by calling (800) 258-4263.
How Supplied:
Tabs 150mg—60; 300mg—30; Soln—240mL
